Moderna said this:
There is typically an extremely high rate of attrition for product candidates across categories of medicines proceeding through clinical trials. These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials.
A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials.
Most investigational medicines that commence clinical trials are never approved as products
Quote~Moderna said this:
There is typically an extremely high rate of attrition for product candidates across categories of medicines proceeding through clinical trials. These product candidates may fail to show the desired safety and efficacy profile in later stages of clinical trials despite having progressed through nonclinical studies and initial clinical trials.
A number of companies in the biopharmaceutical industry have suffered significant setbacks in later-stage clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials.
Most investigational medicines that commence clinical trials are never approved as products
Interesting to note the lack of standards applied to these experimental vaccines.
When hcq is used in late stages of this disease, and due to critical condition prior to administering hcq, and the patient succumbs to geriatric disease or comorbitities, then they claim hcq is killing people.
When these experimental vaccines fail, they respond by saying, no big deal. We expect it due to existing chronic conditions.